Taiga Biotechnologies is a cell-based immunotherapy company focused on harnessing the power of the immune system to fight solid tumors and infectious disease.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/31/2019 | Series C | $27.2MM | $xx.xx | $442.88MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
03/16/2017 | Series B-1 | $12MM | $xx.xx | $29.21MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
25,714,218
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
05/15/2014 | Series B | $3.17MM | $xx.xx | $7.89MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
9,504,687
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
05/30/2012 | Series A | $466,221.00 | $xx.xx | $1.55MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,331,105
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|